At the news
? MIXEDIMPACT 6/10 8-K filed Jul 2, 2026 at 16:20 ET
Pyxis Oncology entered into a securities purchase agreement for a $50 million private placement (plus up to $64 million from warrants) led by BVF Partners, issuing 19.6 million shares at $2.551/share and warrants exercisable at $3.289. Proceeds extend cash runway into Q2 2027 and fund MICVO clinical milestones. The financing is dilutive (~28% of current float) but provides critical capital for a pre-revenue biotech.
- $50M upfront gross proceeds from sale of 19,600,153 shares at $2.551/share
- Warrants to purchase up to 19,600,153 shares at $3.289/share, exercisable after MICVO data disclosure or Oct 1, 2026, expiring July 2, 2029
- Potential total gross proceeds of ~$114M if warrants fully exercised for cash
- Cash runway extended into Q2 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access